Product Name

  • Name

    Cyclosporin A

  • EINECS 200-835-2
  • CAS No. 59865-13-3
  • Article Data18
  • CAS DataBase
  • Density 1.016 g/cm3
  • Solubility ethanol: 30 mg/mL
  • Melting Point 148-151°C
  • Formula C62H111N11O12
  • Boiling Point 1293.8 °C at 760 mmHg
  • Molecular Weight 1202.63
  • Flash Point 736.3 °C
  • Transport Information
  • Appearance White Powder
  • Safety 53-45-36/37-24/25-22
  • Risk Codes 45-60-22-40
  • Molecular Structure Molecular Structure of 59865-13-3 (Cyclosporin A)
  • Hazard Symbols ToxicT, HarmfulXn
  • Synonyms 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine];Ciclosporin;Ciclosporinum [INN-Latin];Cipol N;Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-;Cyclosporine;Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl);Sang 35;Sandimmune (TN);S 7481F1;Restasis;30-ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone;Neoral;(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-pent-3-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-3,6,9,18,24-pentakis(2-methylpropyl)-21-propan-2-yl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone;Sigmasporin Microoral;Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl);Cyclosporin;Consupren;cyclophorine;sandimmun;Sandimmun Neoral;Prestwick_731;Ciclosporin (JP14);Neoplanta;Neoral (TN);Sang-35;(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone;Sandimmune;Antibiotic S 7481F1;OL 27-400;
  • PSA 278.80000
  • LogP 4.14950

Synthetic route

H-D-Ala-MeLeu-MeLeu-MeVal-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-SH

H-D-Ala-MeLeu-MeLeu-MeVal-MeBmt-Abu-Sar-MeLeu-Val-MeLeu-Ala-SH

cyclosporin A
59865-13-3

cyclosporin A

Conditions
ConditionsYield
With Cyclohexyl isocyanide; benzotriazol-1-ol In tetrahydrofuran; dichloromethane at 23℃; for 24h; Inert atmosphere;55%
C117H209N41O23
324077-04-5

C117H209N41O23

A

C55H98N30O11

C55H98N30O11

B

cyclosporin A
59865-13-3

cyclosporin A

Conditions
ConditionsYield
pH=7.4; Reactivity;
7,8-Secocyclosporin-7-carboxylic acid

7,8-Secocyclosporin-7-carboxylic acid

cyclosporin A
59865-13-3

cyclosporin A

Conditions
ConditionsYield
With Cyclohexyl isocyanide; benzotriazol-1-ol In tetrahydrofuran at 70℃; for 16h; Inert atmosphere; Microwave irradiation;6.4 mg
C67H121N11O15

C67H121N11O15

cyclosporin A
59865-13-3

cyclosporin A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: chlorotriisopropylsilane; trifluoroacetic acid / dichloromethane / 1 h / -20 °C
2: Cyclohexyl isocyanide; benzotriazol-1-ol / tetrahydrofuran; dichloromethane / 20 h / 70 °C / Inert atmosphere; Microwave irradiation
View Scheme
C62H113N11O13

C62H113N11O13

cyclosporin A
59865-13-3

cyclosporin A

Conditions
ConditionsYield
With Cyclohexyl isocyanide; benzotriazol-1-ol In tetrahydrofuran; dichloromethane at 70℃; for 20h; Inert atmosphere; Microwave irradiation;8.6 mg
cyclosporin A
59865-13-3

cyclosporin A

acetic anhydride
108-24-7

acetic anhydride

O-acetyl-cyclosporin A
83602-41-9

O-acetyl-cyclosporin A

Conditions
ConditionsYield
With pyridine; dmap In dichloromethane at 0 - 20℃; for 48h; Inert atmosphere;100%
With dmap at 20℃;96%
With dmap In dichloromethane at 20℃;95%
triisopropylsilyl trifluoromethanesulfonate
80522-42-5

triisopropylsilyl trifluoromethanesulfonate

cyclosporin A
59865-13-3

cyclosporin A

C71H131N11O12Si

C71H131N11O12Si

Conditions
ConditionsYield
With 2,6-dimethylpyridine In dichloromethane at 20℃; for 12h;100%
vinyl benzoate
583-04-0

vinyl benzoate

cyclosporin A
59865-13-3

cyclosporin A

A

benzoic acid 6-(5-ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacont-2-yl)-6-hydroxy-5-methyl-hex-2-enyl ester

benzoic acid 6-(5-ethyl-11,17,26,29-tetraisobutyl-14,32-diisopropyl-1,7,10,16,20,23,25,28,31-nonamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacont-2-yl)-6-hydroxy-5-methyl-hex-2-enyl ester

B

benzoylated-MeBMT-CsA

benzoylated-MeBMT-CsA

Conditions
ConditionsYield
With 1,3-dimesityl-4,5-dihydroimidazol-2-ylidenetricyclohexylphos; phine benzylidene ruthenium dichloride In dichloromethane at 45℃; for 12h; Title compound not separated from byproducts;A n/a
B 99%
With tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride In dichloromethane at 45℃; Title compound not separated from byproducts;
S-(4-vinylphenyl) thioacetate
23939-49-3

S-(4-vinylphenyl) thioacetate

cyclosporin A
59865-13-3

cyclosporin A

C69H115N11O13S

C69H115N11O13S

Conditions
ConditionsYield
(1,3-Bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium In dichloromethane for 16h; Heating / reflux;98%
tert-Butyl acrylate
1663-39-4

tert-Butyl acrylate

cyclosporin A
59865-13-3

cyclosporin A

C66H117N11O14

C66H117N11O14

Conditions
ConditionsYield
(1,3-Bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium In dichloromethane for 16h; Heating / reflux;93%
With Hoveyda-Grubbs catalyst second generation In 1,2-dichloro-ethane at 70℃; for 4h; Inert atmosphere; Sealed tube; Microwave irradiation;
With Hoveyda-Grubbs catalyst second generation In 1,2-dichloro-ethane at 23 - 70℃; for 4h; Inert atmosphere; Sealed tube;
cyclosporin A
59865-13-3

cyclosporin A

acetic anhydride
108-24-7

acetic anhydride

MeBmt(OAc)-CsA

MeBmt(OAc)-CsA

Conditions
ConditionsYield
With dmap at 20℃; for 18h;92%
p-vinyl-N-t-butoxycarbonylbenzylamine
150814-00-9

p-vinyl-N-t-butoxycarbonylbenzylamine

cyclosporin A
59865-13-3

cyclosporin A

C73H124N12O14
1245657-05-9

C73H124N12O14

Conditions
ConditionsYield
With tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride In dichloromethane at 55℃; for 20h; Cross Metathesis;91%
With tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride In dichloromethane Reflux;
cyclosporin A
59865-13-3

cyclosporin A

tert-butylpent-4-enyloxydimethylsilane
127154-84-1

tert-butylpent-4-enyloxydimethylsilane

A

C70H129N11O13Si

C70H129N11O13Si

B

TBSO-pentenyl-MeBmt-CsA

TBSO-pentenyl-MeBmt-CsA

Conditions
ConditionsYield
With 1,3-dimesityl-4,5-dihydroimidazol-2-ylidenetricyclohexylphos; phine benzylidene ruthenium dichloride In dichloromethane at 45℃; for 22h; Title compound not separated from byproducts;A n/a
B 90%
With tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidine][benzylidene]ruthenium(II) dichloride In dichloromethane at 45℃; Title compound not separated from byproducts;
tetradecanedioyl dichloride
21646-49-1

tetradecanedioyl dichloride

cyclosporin A
59865-13-3

cyclosporin A

C76H135N11O15

C76H135N11O15

Conditions
ConditionsYield
Stage #1: tetradecanedioyl dichloride; cyclosporin A With dmap at 20℃; for 48h;
Stage #2: With water; sodium hydroxide at 20℃; for 1h;
90%
cyclosporin A
59865-13-3

cyclosporin A

N-succinimidyl 4-pentenoic acid ester
331754-32-6

N-succinimidyl 4-pentenoic acid ester

A

C68H116N12O16

C68H116N12O16

B

C68H116N12O16

C68H116N12O16

Conditions
ConditionsYield
With 1,3-dimesityl-4,5-dihydroimidazol-2-ylidenetricyclohexylphos; phine benzylidene ruthenium dichloride In dichloromethane for 22h; Heating; Title compound not separated from byproducts;A n/a
B 89%
cyclosporin A
59865-13-3

cyclosporin A

Chloroacetic anhydride
541-88-8

Chloroacetic anhydride

cyclosporine A chloroacetate ester
141749-42-0

cyclosporine A chloroacetate ester

Conditions
ConditionsYield
With pyridine at 5 - 20℃; for 17h;88.3%
Bromoform
75-25-2

Bromoform

cyclosporin A
59865-13-3

cyclosporin A

C63H111Br2N11O12

C63H111Br2N11O12

Conditions
ConditionsYield
With N-benzyl-N,N,N-triethylammonium chloride; sodium hydroxide In dichloromethane; water at 20℃; for 120h;87%
methyl 4-vinylbenzoate
1076-96-6

methyl 4-vinylbenzoate

cyclosporin A
59865-13-3

cyclosporin A

C69H115N11O14

C69H115N11O14

Conditions
ConditionsYield
With Hoveyda-Grubbs catalyst second generation In dichloromethane at 60℃; for 48h;86.4%
1,12-dodecanedioyl dichloride
4834-98-4

1,12-dodecanedioyl dichloride

cyclosporin A
59865-13-3

cyclosporin A

C74H131N11O15

C74H131N11O15

Conditions
ConditionsYield
Stage #1: 1,12-dodecanedioyl dichloride; cyclosporin A With dmap at 20℃; for 48h;
Stage #2: With water; sodium hydroxide at 20℃; for 1h;
84%
cyclosporin A
59865-13-3

cyclosporin A

Chloroacetic anhydride
541-88-8

Chloroacetic anhydride

α-chloroacetyl cyclosporin A derivative

α-chloroacetyl cyclosporin A derivative

Conditions
ConditionsYield
With pyridine at 50℃; for 16h;83%
cyclosporin A
59865-13-3

cyclosporin A

suberoyl chloride
10027-07-3

suberoyl chloride

C70H123N11O15

C70H123N11O15

Conditions
ConditionsYield
Stage #1: cyclosporin A; suberoyl chloride With dmap at 20℃; for 48h;
Stage #2: With water; sodium hydroxide at 20℃; for 1h;
82%
cyclosporin A
59865-13-3

cyclosporin A

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-((1R,2R)-1,4-dihydroxy-2-methylbutyl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
116408-18-5

(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-((1R,2R)-1,4-dihydroxy-2-methylbutyl)-30-ethyl-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone

Conditions
ConditionsYield
Stage #1: cyclosporin A With ozone In dichloromethane at -78℃; for 0.5h;
Stage #2: With sodium tetrahydroborate In methanol; dichloromethane at -78 - 20℃; Further stages.;
81%
Multi-step reaction with 2 steps
1.1: ozone / dichloromethane / 0.08 h / -78 °C
1.2: 2 h / -78 - 20 °C
2.1: sodium tetrahydroborate / methanol / 16 h / 0 - 20 °C / Inert atmosphere
View Scheme
sebacoyl chloride
111-19-3

sebacoyl chloride

cyclosporin A
59865-13-3

cyclosporin A

C72H127N11O15

C72H127N11O15

Conditions
ConditionsYield
Stage #1: sebacoyl chloride; cyclosporin A With dmap at 20℃; for 48h;
Stage #2: With water; sodium hydroxide at 20℃; for 1h;
81%
carbon dioxide
124-38-9

carbon dioxide

cyclosporin A
59865-13-3

cyclosporin A

[α-carboxy-sar]-3-cyclosporin

[α-carboxy-sar]-3-cyclosporin

Conditions
ConditionsYield
Stage #1: cyclosporin A With n-butyllithium; diisopropylamine In tetrahydrofuran at -78℃; for 2h; Inert atmosphere;
Stage #2: carbon dioxide In tetrahydrofuran at -78℃; for 1.33333 - 1.41667h;
78%
cyclosporin A
59865-13-3

cyclosporin A

carbonochloridic acid, chloromethyl ester
22128-62-7

carbonochloridic acid, chloromethyl ester

chloromethylcarbonate-CsA
321526-67-4

chloromethylcarbonate-CsA

Conditions
ConditionsYield
With pyridine In dichloromethane; water at 0 - 20℃; for 21.5h;75%
carbon dioxide
124-38-9

carbon dioxide

cyclosporin A
59865-13-3

cyclosporin A

[α-methylene-Sar]-3-cyclosporin

[α-methylene-Sar]-3-cyclosporin

Conditions
ConditionsYield
Stage #1: carbon dioxide; cyclosporin A With lithium diisopropyl amide In tetrahydrofuran; hexane at -5℃; for 0.00338889h; Flow reactor;
Stage #2: With chloroacetyl chloride In tetrahydrofuran; hexane at -50 - 20℃; for 8h; Flow reactor;
65%
H2SiEt2
542-91-6

H2SiEt2

cyclosporin A
59865-13-3

cyclosporin A

C70H133N11O12Si2

C70H133N11O12Si2

Conditions
ConditionsYield
With 2-Allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; bis(pentafluorophenyl)borohydride In chloroform for 24h; Inert atmosphere; Sealed tube;62%
cyclosporin A
59865-13-3

cyclosporin A

3-Chloro-2-methylpropene
563-47-3

3-Chloro-2-methylpropene

C66H117N11O12

C66H117N11O12

Conditions
ConditionsYield
With potassium hydroxide; N-benzyl-N,N,N-triethylammonium chloride In dichloromethane; water55%
3-fluoropropene
818-92-8

3-fluoropropene

cyclosporin A
59865-13-3

cyclosporin A

C62H110FN11O12

C62H110FN11O12

Conditions
ConditionsYield
(1,3-dimesityl-4,5-dihydroimidazol-2-ylidene)(PCy3)Cl2Ru=CHPh In dichloromethane Heating / reflux;51.2%
3-fluoropropene
818-92-8

3-fluoropropene

cyclosporin A
59865-13-3

cyclosporin A

C62H110FN11O12

C62H110FN11O12

Conditions
ConditionsYield
tricyclohexylphosphine[1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-yl-ene][benzylidine]ruthenium(IV)dichloride In dichloromethane Heating / reflux;51.2%
2-chloromethyl-3-chloroprop-1-ene
1871-57-4

2-chloromethyl-3-chloroprop-1-ene

cyclosporin A
59865-13-3

cyclosporin A

C66H116ClN11O12
158613-16-2

C66H116ClN11O12

Conditions
ConditionsYield
With potassium hydroxide; N-benzyl-N,N,N-triethylammonium chloride In dichloromethane; water50%
cyclosporin A
59865-13-3

cyclosporin A

[4’-hydroxy-N-methylleucine]4-cyclosporin A
107335-26-2

[4’-hydroxy-N-methylleucine]4-cyclosporin A

Conditions
ConditionsYield
With Sebekia benihana; water In ethanol50%
cyclosporin A
59865-13-3

cyclosporin A

methyl iodide
74-88-4

methyl iodide

A

C63H113N11O12

C63H113N11O12

B

C63H113N11O12

C63H113N11O12

Conditions
ConditionsYield
Stage #1: cyclosporin A With lithium chloride; lithium diisopropyl amide In tetrahydrofuran; hexane at -78 - 0℃; for 2h; Inert atmosphere;
Stage #2: methyl iodide In tetrahydrofuran at -20℃; for 3h; Inert atmosphere;
A 50%
B 12%

Cyclosporin A Chemical Properties

Molecular Structure:

Molecular Formula: C62H111N11O12
Molecular Weight: 1202.6112
IUPAC Name: (2S,5S,8S,11S,14R,17S,20S,23S,26S,32S)-32-ethyl-2-[(E,1R,2R)-1-Hydroxy-2-methylhex-4-enyl]-3,6,9,12,14,17,21,27,30-nonamethyl-8,11,20,26-tetrakis(2-methylpropyl)-5,23-di(propan-2-yl)-3,6,9,12,15,18,21,24,27,30,33-undecazacyclotritriacontane-1,4,7,10,13,16,19,22,25,28,31-undecone
Classification Code: Anti-Infective Agents ; Antifungal agents ; Antirheumatic agents ; Dermatologic agents ; Drug / Therapeutic Agent ; Enzyme inhibitors ; Human Data ; Immunologic Factors ; Immunosuppressant ; Immunosuppressive agents ; Mutation data ; Reproductive Effect ; Tumor data
Melting point: 148-151°C 
Index of Refraction: 1.467
Molar Refractivity: 328.83 cm3
Molar Volume: 1183.6 cm3
Surface Tension: 31.6 dyne/cm
Density: 1.016 g/cm3
Flash Point: 736.3 °C
Enthalpy of Vaporization: 218.52 kJ/mol
Boiling Point: 1293.8 °C at 760 mmHg

Cyclosporin A Uses

 Cyclosporine (CAS NO.59865-13-3) is an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system and, so, the risk of organ rejection. It has been studied in transplants of skin, heart, kidney, liver, lung, pancreas, bone marrow, and small intestine.

Cyclosporin A Production

 Cyclosporine (CAS NO.59865-13-3) is synthesized by a nonribosomal peptide synthetase, cyclosporine synthetase. The enzyme contains an adenylation domain, a thiolation domain, a condensation domain, and an N-methyltransferase domain. The adenylation domain is responsible for substrate recognition and activation, whereas the thiolation domain covalently binds the adenylated amino acids to phosphopantetheine and the condensation domain elongates the peptide chain. Cyclosporine synthetase substrates include L-VALINE, l-LEUCINE, l-ALANINE, L-Glycine, 2-aminobutyric acid, 4-methylThreonine, and D-alanine. With the adenylation domain, cyclosporine synthetase generates the acyl-adenylated amino acids, then covalently binds the amino acid to phosphopantetheine through a thioester linkage. Some of the amino acid substrates become N-methylated by S-Adenosyl methionine. The cyclization step releases cyclosporine A from the enzyme.  Amino acids such as D-Ala and butenyl-methyl-L-Threonine indicates that cyclosporine synthetase requires the action of other enzymes such as a D-alanine racemase. The racemization of L-Ala to D-Ala is pyridoxal phosphate-dependent. The formation of butenyl-methyl-L-Threonine is performed by a butenyl-methyl-L-Threonine polyketide synthase that utilizes acetate/malonate as its starting material.

Cyclosporin A Toxicity Data With Reference

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo oral 12mg/kg (12mg/kg) VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION

ENDOCRINE: ANTIDIURESIS
Journal of Hypertension. Vol. 11, Pg. 1209, 1993.
man TDLo oral 14286ug/kg (14.286mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: EXCITEMENT

CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)
Annals of Pharmacotherpy. Vol. 34, Pg. 405, 2000.
man TDLo oral 20mg/kg/2D-I (20mg/kg) BEHAVIORAL: HEADACHE

VASCULAR: ACUTE ARTERIAL OCCLUSION

LUNGS, THORAX, OR RESPIRATION: CYANOSIS
Lancet. Vol. 2, Pg. 1092, 1986.
man TDLo parenteral 20mg/kg/5D-I (20mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

SENSE ORGANS AND SPECIAL SENSES: DIPLOPIA: EYE

SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE
American Journal of Ophthalmology. Vol. 126, Pg. 607, 1998.
man TDLo unreported 30mg/kg/4D-I (30mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" Annals of Internal Medicine. Vol. 107, Pg. 786, 1987.
mouse LD50 intravenous 96mg/kg (96mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
mouse LD50 oral 2329mg/kg (2329mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

SKIN AND APPENDAGES (SKIN): HAIR: OTHER

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Archives of Toxicology. Vol. 53, Pg. 107, 1983.
rabbit LD50 intravenous 10mg/kg (10mg/kg)   Toxicologic Pathology. Vol. 14, Pg. 73, 1986.
rabbit LD50 oral > 1gm/kg (1000mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

SKIN AND APPENDAGES (SKIN): HAIR: OTHER

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
Archives of Toxicology. Vol. 53, Pg. 107, 1983.
rat LD50 intraperitoneal 147mg/kg (147mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
rat LD50 intravenous 24mg/kg (24mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
rat LD50 oral 1480mg/kg (1480mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Archives of Toxicology. Vol. 53, Pg. 107, 1983.
rat LD50 subcutaneous 286mg/kg (286mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 17, Pg. 365, 1986.
women TDLo oral 62500ug/kg/5D (62.5mg/kg) KIDNEY, URETER, AND BLADDER: OTHER CHANGES Lancet. Vol. 1, Pg. 1221, 1986.
women TDLo oral 1911mg/kg/91W (1911mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: COMA

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"
British Journal of Rheumatology. Vol. 33, Pg. 90, 1994.

Cyclosporin A Safety Profile

Hazard Codes of Cyclosporine (CAS NO.59865-13-3): ToxicT,HarmfulXn
Risk Statements: 45-60-22-40 
R45: May cause cancer. 
R60: May impair fertility. 
R22: Harmful if swallowed. 
R40: Limited evidence of a carcinogenic effect.
Safety Statements: 53-45-36/37-24/25-22 
S53: Avoid exposure - obtain special instructions before use. 
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
S36/37: Wear suitable protective clothing and gloves. 
S24/25: Avoid contact with skin and eyes. 
S22: Do not breathe dust.
WGK Germany: 3
RTECS: GZ4120000

Cyclosporin A Specification

 Synonyms of Cyclosporin A (CAS NO.59865-13-3) are (R-(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) ; Abrammune ; Antibiotic S 7481F1 ; Arpimune ME ; CCRIS 1590 ; Cicloral ; Cicloral (antibiotic) ;  Cyclo(((E)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl) ; Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl) ; Cyclosporin rine ; DRG-0275 ; Debio088 ; Equoral ; Gengraf ; HSDB 6881 ; Imusporin ; NSC 290193 ; Neoplanta ; Neoral ; OL 27-400 ; Optimmune ; Papilock Mini ; Ramihyphin A ; Restasis ; S 7481F1 ; S-Neoral ; SDZ-OXL 400 ; Sandimmun ; Sandimmun Neoral ; Sandimmune ; Sandimmune Neoral ; Sang 35 ; Sang-35 ; Sangcya ; Sigmasporin Microoral ; UNII-83HN0GTJ6D ; Zinograf ME .

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View